Pfizer
NEWS
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
There was a handful of positive clinical trial news reported today. Here’s a look.
Pfizer and Mylan are less than two weeks away from finalizing the merger of the generic drugmaker with Pfizer’s Upjohn business unit.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Pfizer indicated yesterday that its Phase III clinical trial of 44,000 volunteers now needs fewer than 2,000 people to be fully enrolled.
Two years ago, Cerevel Therapeutics spun out of Pfizer. It then took an unusual approach, merging with a special purpose acquisition company, Arya Sciences Acquisition Corp II. Arya was designed specifically to acquire or merge with another company.
Arixa Pharmaceuticals announced on Thursday that Pfizer’s hospital business has agreed to acquire the company. Arixa has been developing oral antibiotics for antibiotic-resistant Gram-negative infections.
Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample. They published the research today in The Lancet eClinicalMedicine.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
JOBS
IN THE PRESS